Levalbuterol Hydrochloride

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Virtual Booth

Contact Supplier

Check COS database
Check all USDMF suppliers

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

21 API Suppliers, 7 USDMF, 2 EU WC, 5 NDC API, 15 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

8 Drugs in Development

8 Drugs in Development

FINISHED DOSAGE FORMULATIONS

31 FDF Dossiers, 31 FDA Orange Book

DRUG PRODUCT COMPOSITIONS

SOLUTION;INHALATION - EQ 0.0103% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INHALATION - EQ 0.021% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INHALATION - EQ 0.042% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INHALATION - EQ 0.25% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 Kirsch Pharma, 5 Actylis

EXCIPIENTS BY APPLICATIONS

5 Parenteral, 2 Controlled & Modified Release, 1 Thickeners and Stabilizers

DIGITAL CONTENT

7 News #PharmaBuzz

7 News #PharmaBuzz

GLOBAL SALES INFORMATION

11 US Medicaid Prescriptions, 5 Regulatory FDF Prices, 5 Annual Reports

MARKET PLACE

3 APIs

3 APIs

REF. STANDARDS & IMPURITIES

2 Others

2 Others

Xls

Filters

Company Name

Year

DEALS // DEV.

Country

Sponsor

Therapeutic Area

Study Phase

Deal Type

Product Type

Dosage Form

Lead Product

Target

Filters

Reset Filter

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Sanofi

France

CPhI WW Frankfurt

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Levalbuterol Hydrochloride

Therapeutic Area : Pulmonary/Respiratory Diseases

Study Phase : Approved FDF

Sponsor : Lupin Ltd

Deal Size : Undisclosed

Deal Type : Acquisition

DEALS_DEV

Lupin Atlantis Holdings to Acquire Accretive Established Products in Europe and Canada from Sanofi

Details : Through th acquisition, Lupin expand its portfolio of accretive established products in Europe and Canada, including Xopenex (levalbuterol HCl), a short-acting β₂ adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulm...

Product Name : Xopenex

Product Type : HPAPI

Upfront Cash : Undisclosed

December 23, 2023

Lead Product(s) : Levalbuterol Hydrochloride

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Approved FDF

Sponsor : Lupin Ltd

Deal Size : Undisclosed

Deal Type : Acquisition

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

02

Sumitomo Pharma America

U.S.A

OPRD

Not Confirmed

03

Fahim Khorfan, MD

Country

OPRD

Not Confirmed

Find Clinical Drug Pipeline Developments & Deals for Levalbuterol Hydrochloride